Since IDO is a powerful suppressant of T cell function, this ineffectiveness of the IDO pathway to control M. tuberculosis in vivo, coupled with the strong induction of IDO in TB granulomas, together suggest that blockade of IDO activity in vivo may also serve as an attractive host-directed therapy (HDT) target for TB. Here, IDO1 is linked to tuberculosis.